Hester Biosciences shareholding pattern

·Pharma & Health Chart ›

Who owns itSep 2026 quarter

Promoters44.28%−9.45 pts

Foreign investors (FII)0.31%no change

Domestic institutions (DII)0.08%+0.08 pts

of which mutual funds0.00%no change

Public55.33%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,243.70

Hester Biosciences Limited

· Pharma & Health

₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,909 Cr

Holding % of Total Shares 12 Months Ending	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Promoter & Group	53.73	53.73	53.73	53.73	53.73	53.73	53.73	53.73	53.73	44.28
FII / FPI	0.52	0.61	0.59	0.87	0.52	0.53	0.51	0.38	0.31	0.31
DII	0.00	0.02	0.02	0.02	0.02	0.00	0.01	0.00	0.00	0.08

Latest: 2026-09-30 · 21 quarters of history · click a row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.